Composite renal endpoints: was ACCOMPLISH accomplished?

The Lancet

Volumn 375, Issue 9721, 2010, Pages 1140-1142

  Heerspink, Hiddo Lambers ^a   de Zeeuw, Dick ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BENAZEPRIL; CHLOROTHIAZIDE;

ARTICLE; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; PRIORITY JOURNAL; RENAL PROTECTION; RENOVASCULAR HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 77950300833     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60098-0     Document Type: Note

References (10)

1. Brenner B.M., Cooper M.E., de Zeeuw D., et al., for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
2. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P., and for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
3. Bakris G.L., Sarafidis P.A., Weir M.R., et al., for the ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet (2010) 10.1016/S0140-6736(09)62100-0 published online Feb 18.
4. Jamerson K., Weber M.A., Bakris G.L., et al., for the ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359 (2008) 2417-2428
5. Vogt L., Waanders F., Boomsma F., de Zeeuw D., and Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 19 (2008) 999-1007
6. Herlitz H., Harris K., Risler T., et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant 16 (2001) 2158-2165
7. Bakris G.L., and Weir M.R. Angiotensin converting enzyme inhibitor-associated elevations in serum creatinine is this a cause for concern?. Arch Intern Med 160 (2000) 685-693
8. Delles C., Klingbeil A.U., Schneider M.P., Handrock R., Weidinger G., and Schmieder R.E. Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. Am J Hypertens 16 (2003) 1030-1035
9. Sarafidis P.A., Bakris G., Weber M., et al. Changes in glomerular filtration rate with benazepril plus amlodipine or benazepril plus hydrochlorothiazide treatment in hypertensive patients at high risk; an analysis of the ACCOMPLISH trial. World Congress of Nephrology, Milan, Italy; May 23, 2009: Sa199 (abstr). http://www.abstracts2view.com/wcn/view.php?nu=WCN09L_455 (accessed Jan 7, 2010).
10. Klahr S., Levey A.S., Beck G., et al., for the Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 330 (1994) 877-884